• 1
    Amant F, Moerman P, Neven P et al. Endometrial cancer. Lancet 2005; 366: 491505.
  • 2
    Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer 1985; 56: 40312.
  • 3
    Sherman AI, Brown S. The precursors of endometrial carcinoma. Am J Obstet Gynecol 1979; 135: 94756.
  • 4
    Kendall BS, Ronnett BM, Isacson C et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. Am J Surg Pathol 1998; 22: 10129.
  • 5
    Mutter GL, Baak JP, Crum CP et al. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. J Pathol 2000; 190: 4629.
  • 6
    Deligdisch L, Kase NG, Bleiweiss IJ. Endometrial cancer in elderly women: a histologic and steroid receptor study. Gerontology 2000; 46: 1721.
  • 7
    Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 204254.
  • 8
    Fearnhead NS, Britton MP, Bodmer WF. The ABC of APC. Hum Mol Genet 2001; 10: 72133.
  • 9
    Behrens J, Von Kries JP, Kuhl M et al. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996; 382: 63842.
  • 10
    Fujimoto J, Ichigo S, Hori M et al. Expressions of E-cadherin and alpha- and beta-catenin mRNAs in uterine endometrial cancers. Eur J Gynaecol Oncol 1998; 19: 7881.
  • 11
    Christofori G, Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci 1999; 24: 736.
  • 12
    Fodde R. The APC gene in colorectal cancer. Eur J Cancer 2002; 38: 86771.
  • 13
    Gamallo C, Palacios J, Moreno G et al. beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 1999; 155: 52736.
  • 14
    Moreno-Bueno G, Hardisson D, Sanchez C et al. Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene 2002; 21: 798190.
  • 15
    Sparks AB, Morin PJ, Vogelstein B et al. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998; 58: 11304.
  • 16
    Stawerski P, Wagrowska-Danilewicz M, Stasikowska O et al. Immunoexpression of beta-catenin – E-cadherin complex in primary serous ovarian tumors. Pol J Pathol 2008; 59: 2732.
  • 17
    Esteller M, Corn PG, Baylin SB et al. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 32259.
  • 18
    Virmani AK, Rathi A, Sathyanarayana UG et al. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin Cancer Res 2001; 7: 19982004.
  • 19
    Lambertz S, Ballhausen WG. Identification of an alternative 5′ untranslated region of the adenomatous polyposis coli gene. Hum Genet 1993; 90: 6502.
  • 20
    Zysman M, Saka A, Millar A et al. Methylation of adenomatous polyposis coli in endometrial cancer occurs more frequently in tumors with microsatellite instability phenotype. Cancer Res 2002; 62: 36636.
  • 21
    Banno K, Yanokura M, Susumu N et al. Relationship of the aberrant DNA hypermethylation of cancer-related genes with carcinogenesis of endometrial cancer. Oncol Rep 2006; 16: 118996.
  • 22
    Droufakou S, Deshmane V, Roylance R et al. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer 2001; 92: 4048.
  • 23
    Kallakury BV, Sheehan CE, Winn-Deen E et al. Decreased expression of catenins (alpha and beta), p120 CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas. Cancer 2001; 92: 278695.
  • 24
    Saito T, Nishimura M, Yamasaki H et al. Hypermethylation in promoter region of E-cadherin gene is associated with tumor dedifferention and myometrial invasion in endometrial carcinoma. Cancer 2003; 97: 10029.
  • 25
    Pijnenborg JM, Kisters N, Van Engeland M et al. APC, beta-catenin, and E-cadherin and the development of recurrent endometrial carcinoma. Int J Gynecol Cancer 2004; 14: 94756.
  • 26
    Dong SM, Kim HS, Rha SH et al. Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res 2001; 7: 19826.
  • 27
    Herman JG, Graff JR, Myohanen S et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 98216.
  • 28
    Ignatov A, Bischoff J, Schwarzenau C et al. P16 alterations increase the metastatic potential of endometrial carcinoma. Gynecol Oncol 2008; 111: 36571.
  • 29
    Cattoretti G, Becker MH, Key G et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992; 168: 35763.
  • 30
    Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182: 31122.
  • 31
    Semczuk A, Skomra D, Cybulski M et al. Immunohistochemical analysis of MIB-1 proliferative activity in human endometrial cancer. Correlation with clinicopathological parameters, patient outcome, retinoblastoma immunoreactivity and K-ras codon 12 point mutations. Histochem J 2001; 33: 193200.
  • 32
    Horree N, Van Diest PJ, Van Der GP et al. Progressive derailment of cell cycle regulators in endometrial carcinogenesis. J Clin Pathol 2008; 61: 3642.
  • 33
    Blechschmidt K, Kremmer E, Hollweck R et al. The E-cadherin repressor snail plays a role in tumor progression of endometrioid adenocarcinomas. Diagn Mol Pathol 2007; 16: 2228.
  • 34
    Sakuragi N, Nishiya M, Ikeda K et al. Decreased E-cadherin expression in endometrial carcinoma is associated with tumor dedifferentiation and deep myometrial invasion. Gynecol Oncol 1994; 53: 1839.
  • 35
    Scholten AN, Aliredjo R, Creutzberg CL et al. Combined E-cadherin, alpha-catenin, and beta-catenin expression is a favorable prognostic factor in endometrial carcinoma. Int J Gynecol Cancer 2006; 16: 137985.
  • 36
    Gassel AM, Backe J, Krebs S et al. Endometrial carcinoma: immunohistochemically detected proliferation index is a prognosticator of long-term outcome. J Clin Pathol 1998; 51: 259.
  • 37
    Agrawal A, Murphy RF, Agrawal DK. DNA methylation in breast and colorectal cancers. Mod Pathol 2007; 20: 71121.
  • 38
    Fraga MF, Esteller M. Epigenetics and aging: the targets and the marks. Trends Genet 2007; 23: 4138.
  • 39
    Shames DS, Minna JD, Gazdar AF. DNA methylation in health, disease, and cancer. Curr Mol Med 2007; 7: 85102.